Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics' development of Casgevy helped validate its gene-editing platform. The company's innovative approach should yield more solid clinical and regulatory wins in the next five years.
CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for ...
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
CRISPR can be used to suppress mutations which cause gain of function, and also to repair mutations causing loss of function in neurological disorders. [199] The gene editing tool has become a foothold in vivo application for assimilation of molecular pathways. CRISPR is unique to the development of solving neurological diseases for several ...
For premium support please call: 800-290-4726 more ways to reach us
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]
For premium support please call: 800-290-4726 more ways to reach us